Sumatriptan - GlaxoSmithKline

Drug Profile

Sumatriptan - GlaxoSmithKline

Alternative Names: Imigran Nasal Spray; Imitrex Nasal Spray

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antimigraines; Indoles; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine
  • No development reported Menstrual migraine

Most Recent Events

  • 22 Feb 2016 First Generic equivalent complex product Imitrex® nasal spray approved in USA for Migrane
  • 04 Oct 2013 Launched for Migraine in Argentina, Canada, Indonesia and Israel before 4 October 2013 under the trade name Imitrex® (Intranasal)
  • 02 Feb 2006 Registered for Migraine in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top